Dr. Weiss on Immunotherapy Combinations in Head and Neck Cancer

Partner | Cancer Centers | <b>UNC LINEBERGER</b>

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.

In addition to the approved PD-1 agents, PD-L1 agents will soon be used in the recurrent metastatic setting, says Weiss. Data with combinations of CTLA-4 agents such as ipilimumab (Yervoy) and nivolumab (Opdivo) or durvalumab (Imfinzi) and tremelimumab will be reported in the coming months, as well.

The combination of PD-1 and IDO inhibitors is also showing promise, Weiss says.